Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs.

ABSTRACT:

Background

Rodent cancer models have limitations in predicting efficacy, tolerability and accompanying biomarkers of ICIs in humans. Companion dogs suffering from neoplastic diseases have gained attention as a highly relevant translational disease model. Despite successful reports of PD-1/PD-L1 blockade in dogs, no compounds are available for veterinary medicine.

Methods

Here, we assessed suitability of seven FDA-approved human ICIs to target CTLA-4 or PD-1/PD-L1 in dogs. Cross-reactivity and blocking potential was assessed using ELISA and flow cytometry. Functional responses were assessed on peripheral blood mononuclear cells (PBMCs) derived from healthy donors (n = 12) and cancer patient dogs (n = 27) as cytokine production after stimulation. Immune compositi

SUBMITTER: Pantelyushin S 

PROVIDER: S-EPMC7918463 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature